Literature DB >> 32598800

[The cough variant asthma].

M O Uryasjev1, I V Ponomareva1, M Bhar1, S I Glotov1.   

Abstract

Cough variant asthma (CVA) was first described by W. Corrao. CVA was described as the isolated chronic cough as the only presenting symptom responsive to bronchodilator therapy.This phenotype of asthma is present with airway hyperresponsiveness, eosinophilic inflammation airways and bronchodilator responsive coughing without typical manifestation of asthma such as wheezing or dyspnea. CVA shares common features with classic asthma such as eosinophilic inflammation and airway remodeling. Because of that, CVA is clinically considered as a variant type of asthma.

Entities:  

Keywords:  airway hyperreactivity; asthma; chronic cough; cough variant asthma

Mesh:

Substances:

Year:  2020        PMID: 32598800     DOI: 10.26442/00403660.2020.03.000404

Source DB:  PubMed          Journal:  Ter Arkh        ISSN: 0040-3660            Impact factor:   0.467


  4 in total

1.  Mechanism of Action of Yin Nourishing and Heat Clearing Prescription in Treating Cough Variant Asthma Based on Network Pharmacology and Molecular Docking Verification.

Authors:  Yin Zhang; Yixin Cui; Qi Chen; Fagen Li; Shaodan Li
Journal:  Comput Math Methods Med       Date:  2022-07-12       Impact factor: 2.809

2.  Allergic shiners in a patient with cough-variant asthma: a case report.

Authors:  Mahsa Rekabi; Nasim Raad; Atefeh Abedini; Sepideh Darougar; Ali Akbar Velayati
Journal:  J Med Case Rep       Date:  2022-05-28

3.  The effect of montelukast sodium plus budesonide on the clinical efficacy, inflammation, and pulmonary function in children with cough variant asthma.

Authors:  Lijuan Chen; Manqin Huang; Nanli Xie
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

4.  Exploration in the Mechanism of Zhisou San for the Treatment of Cough Variant Asthma Based on Network Pharmacology.

Authors:  De-Hai Guo; Jin-Ping Hao; Xing-Jie Li; Qing Miao; Qiong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.